ANANDRATHI

India | Equities

Asbestos Cement Sheets Company Update

Change in Estimates 🗹 Target 🗹 Reco 🗆

30 May 2017

Visaka Industries

Outstripping the industry; we maintain a Buy

With Visaka's strong brand equity and its boards capacity expansion, in the next two years, the division would post a robust 21% revenue CAGR. The ACS division is expected to do well, backed by rising demand for rural housing. After the ramped up capacity, we expect a 13% revenue CAGR in the yarn division. Improved margin and lower interest cost would lead to a 24% CAGR in profits. We maintain our Buy recommendation, with a TP of ₹470 (₹302 earlier).

Boards to grow sturdily. On Visaka's strong brand equity and capacity expansion, its boards division would report a 21% revenue CAGR over FY17-19. Further, rural-housing demand would boost the ACS division. We expect 6% revenue CAGR in the ACS division. The higher proportion of Boards in revenue is expected to lead to an expanded margin. We expect a 63bp improved margin over the next two years. The company continues to outperform even in the tough industry scenario.

Yarn division to ramp up, post-expansion. On the 26% capacity increase, the yarn-division revenue would come at a 13% CAGR in the next two years. The margin would be better due to the ramped up volumes from the fresh capacity. Management expects a better performance ahead from the division.

Improved financials. Working capital improved in FY17 and debt was reduced. Management plans to reduce debt further. Margin expansion due to the higher share of Boards, better working-capital and lower debt would lead to a 24% profit CAGR over FY17-19. In FY18 the company is expanding its Boards capacity in the North by 50,000 tons at capex of ₹650m-700m.

Valuation. Rising disposable incomes and the government's thrust on infrastructure and rural housing would help Visaka do well in future. We retain our Buy recommendation. We assign a PE of 12x FY19e EPS, arriving at a target of ₹470. At the CMP, the stock is quoting at PE of 11.4x FY18e and 9.7x FY19e. **Risk.** Rise in input costs.

Key financials (YE Mar)	FY15	FY16	FY17	FY18e	FY19e
Sales (₹ m)	10,211	10,049	9,667	10,766	11,831
Net profit (₹ m)	212	244	408	530	624
EPS (₹)	13.3	15.3	25.6	33.3	39.2
Growth (%)	77.4	15.1	67.0	29.9	17.7
PE (x)	28.6	24.8	14.9	11.4	9.7
PBV (x)	1.8	1.7	1.6	1.4	1.3
RoE (%)	6.4	7.2	11.1	13.0	13.7
RoCE (%)	8.4	8.7	11.8	14.0	15.4
Dividend yield (%)	1.3	1.3	1.6	1.6	1.6
Net debt/equity (x)	0.8	0.8	0.5	0.5	0.4
Source: Company, Anand Rathi Research					

Rating: Buy
Target Price: ₹470
Share Price: ₹381

Key data	VSKI IN / VSKI.BO					
52-week high/low	₹392/₹137					
Sensex/Nifty		311	59/9625			
3-m average volume			\$0.6m			
Market cap		₹6bn	/\$93.3m			
Shares outstanding			16m			
Shareholding pattern (%)	Mar'17	Dec'16	Sep'16			
Promoters	41.2	37.6	37.6			
- of which, Pledged	-	-	-			
Free Float	58.8	62.4	62.5			
- Foreign institutions	0.3	3.6	2.9			
- Domestic institutions	3.6	0.4	0.5			
- Public	54.9	58.3	59.1			
Estimates revision (%)		FY18e	FY19e			
Sales		(6.2)	(5.9)			

(1.4)

10.2

(4.9)

3.7



EBITDA

PAT

Girish Solanki Research Analyst +9122 66266712 girishsolanki@rathi.com

Prateek Pareek Research Analyst +9122 66266814 prateekpareek@rathi.com


Anand Rathi Shares and Stock Brokers Limited (hereinafter "ARSSBL") is a full service brokerage and equities research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in Appendix.

Quick Glance – Financials and Valuations

Year-end:Mar	FY15	FY16	FY17e	FY18e	FY19e
Net revenues	10,211	10,049	9,667	10,766	11,831
Revenue growth (%)	14.5	(1.6)	(3.8)	11.4	9.9
- Oper. expenses	9,252	9,096	8,520	9,452	10,352
EBIDTA	959	952	1,148	1,313	1,479
EBITDA margins (%)	9.4	9.5	11.9	12.2	12.5
- Interest	220	213	180	156	139
- Depreciation	431	363	341	376	418
+ Other income	24	27	38	22	24
- Tax	120	159	256	273	321
Effective tax rate (%)	36.1	39.5	38.5	34.0	34.0
+ Associates / (minorities)	0	0	0	0	0
Adjusted PAT	212	244	408	530	624
+ Extraordinary items	0	0	0	0	0
Reported PAT	212	244	408	530	624
Adj. FDEPS (₹ / sh)	13.3	15.3	25.6	33.3	39.2
Adj. FDEPS growth (%)	77.4	15.1	67.0	29.9	17.7

Fig 3 – Cash-flow statement (₹ m)

Year-end: Mar	FY15	FY16	FY17e	FY18e	FY19e
Adjusted PAT	212	244	408	530	624
+ Non-cash items	392	327	332	376	418
Cash profit	605	571	740	906	1,042
- Incr. / (decr.) in WC	762	423	(493)	383	186
Operating cash-flow	(157)	148	1,233	523	856
- Capex	2	219	744	500	350
Free cash-flow	(159)	(71)	489	23	506
- Dividend	96	96	112	112	112
+ Equity raised	-	-	-	-	-
+ Debt raised	398	591	(957)	(200)	(300)
- Investments	(5)	(45)	(101)	-	-
- Misc. items	129	0	(112)	(0)	0
Net cash-flow	20	469	(367)	(289)	94
+ Op. cash & bank bal.	261	281	750	383	94
Cl. Cash & bank bal.	281	750	383	94	189
Source: Company, Anand Rat	hi Research				






Year-end: Mar	FY15	FY16	FY17e	FY18e	FY19e
Share capital	159	159	159	159	159
Reserves & surplus	3,163	3,311	3,719	4,138	4,650
Net worth	3,322	3,471	3,879	4,297	4,809
Total debt	2,860	3,451	2,494	2,294	1,994
Minority interest	0	0	0	0	0
Def. tax liab. (net)	258	222	213	213	213
Capital employed	6,440	7,144	6,586	6,805	7,017
Net fixed assets	3,111	2,968	3,371	3,495	3,428
Intangible assets	14	14	14	14	15
Investments	146	101	0	0	0
- of which, Liquid					
Working capital	2,888	3,311	2,818	3,201	3,387
Cash	281	750	383	94	189
Capital deployed	6,440	7,144	6,586	6,805	7,018
Working capital (days)	103	120	106	109	104
Book value (₹ / sh)	209	218	244	270	302

Fig 4 – Ratio analysis @ ₹381

FY15	FY16	FY17e	FY18e	FY19e
28.6	24.8	14.9	11.4	9.7
9.4	10.0	8.1	6.7	5.8
9.0	9.2	7.1	6.3	5.3
0.8	0.9	0.8	0.8	0.7
1.8	1.7	1.6	1.4	1.3
6.4	7.2	11.1	13.0	13.7
8.4	8.7	11.8	14.0	15.4
1.3	1.3	1.6	1.6	1.6
45.0	39.1	27.4	21.1	17.9
0.8	0.8	0.5	0.5	0.4
40	50	57	55	55
78	88	81	81	78
78	74	75	75	75
57	57	51	52	52
3.1	3.3	3.0	3.1	3.4
	28.6 9.4 9.0 0.8 1.8 6.4 8.4 1.3 45.0 0.8 40 78 78 78 57	28.6 24.8 9.4 10.0 9.0 9.2 0.8 0.9 1.8 1.7 6.4 7.2 8.4 8.7 1.3 1.3 45.0 39.1 0.8 0.8 40 50 78 88 78 74 57 57	28.6 24.8 14.9 9.4 10.0 8.1 9.0 9.2 7.1 0.8 0.9 0.8 1.8 1.7 1.6 6.4 7.2 11.1 8.4 8.7 11.8 1.3 1.3 1.6 45.0 39.1 27.4 0.8 0.8 0.5 40 50 57 78 88 81 78 74 75 57 57 51	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

Fig 6 – Segment-wise revenue break-up (FY17)



Company update


Revenue of Visaka's building products (BP) division shrank slightly in FY17. Even in the recent tough environment with the industry contracting 5% during FY17, the company outstripped it in performance. Lower material costs helped its margins expand during the year.


The performance of the yarn division was hit in the last quarter due to lower utilisation at the newly-expanded capacity and the resulting higher costs.

The Boards division is operating at \sim 75%, which the company expects to rise on the back of robust demand. In ACS, the company is operating at 85% capacity.

The margin of the BP division was robust while that of the yarn division fell on account of lower utilisation at the new capacity. The drop in exports was counter balanced by a 27% increase in domestic sales.

Visaka is expanding its Boards capacity in the North, by 50,000 tons in FY18, at capex of ₹650m-700m. Better working capital helped it shrink its debt during FY17. We believe it will continue to outpace the industry over FY17-19, bolstered by growth in its Boards and Yarn divisions.





Valuation

We believe that the expansion in Boards and Yarn would drive volume growth in the next two years, which would be supported by modest growth in the ACS Division. The 2.5-MW solar plant at Miryalguda for its own use and the plant in Pune have been adding to growth.

We expect the operating margin in the next two years to come at ~12.5%. Because of its strong brand, Visaka's Boards division is expected to post robust numbers. We believe that, with the government thrust, the ACS division is likely to grow 6% in the next two years. The FY18e and FY19e RoCE are expected to come at respectively 13% and 13.7%.

On the back of the margin expansion and lower interest expenses, we believe the company would post a 24% CAGR in PAT over FY17-19. To account for the strong earnings growth, we assign a PE of 12x to FY19e EPS and arrive at a revised target of ₹470. At the ruling price, the stock is trading at PE of 11.4x FY18e and 9.7x FY19e. We retain our Buy recommendation on it.

Fig 10 – Change in estimates


5 5		FY18			FY18		FY19		
(₹ m)	New	Old	Var%	New	Old	Var%			
Sales	10,766	11,480	(6.2)	11,831	12,567	(5.9)			
EBITDA	1,313	1,332	(1.4)	1,479	1,555	(4.9)			
PAT	530	481	10.2	624	602	3.7			





Risks

- Volatile raw-material prices. Its incapacity because of competition to pass on to consumers the rise in raw-material costs could lead to margins contracting.
- Competition may lead to pressure on prices. The company is faced with keen competition from the informal market; therefore, pricing has to be considered with this in mind.
- Activities of the 'Ban Asbestos' lobby. Activities of this lobby, instituted by manufacturers of substitute products, are an ongoing issue.



Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)				
	Buy	Hold	Sell	
Large Caps (>US\$1bn)	>15%	5-15%	<5%	
Mid/Small Caps (<us\$1bn)< td=""><td>>25%</td><td>5-25%</td><td><5%</td><td></td></us\$1bn)<>	>25%	5-25%	<5%	

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX), United Stock Exchange and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL to its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report? ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No

Other Disclosures pertaining to distribution of research in the United States of America

This report was prepared, approved, published and distributed by the Anand Rathi Share and Stock Brokers Limited (ARSSBL) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of ARSSBL only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital. ARSSBL accepts responsibility for its contents. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital LLC at 646-454-8600

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

This material was produced by ARSSBL, solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC (19 West 44th Street, Suite 1700, New York, NY 10036) and elsewhere in the world by ARSSBL or an authorized affiliate of ARSSBL (such entities and any other entity, directly or indirectly, controlled by ARSSBL, the "Affiliates"). This document does not constitute an offer of, or an invitation by or on behalf of ARSSBL or its Affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which ARSSBL or its Affiliates consider to be reliable. None of ARSSBL or its Affiliates accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.

2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.

3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.

4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.

5. As of the publication of this report, ARSSBL does not make a market in the subject securities.

6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

Enclave Capital LLC is distributing this document in the United States of America. ARSSBL accepts responsibility for its contents. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital LLC.

© 2016. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: 4th Floor, Silver Metropolis, Jaicoach Compound, Opposite Bimbisar Nagar, Goregaon (East), Mumbai - 400 063. Tel No: +91 22 4001 3700 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.